Bronchiectasis: the arrival of better evidence
MetadataShow full item record
Bronchiectasis unrelated to cystic fibrosis is increasingly recognised as a major contributor to respiratory morbidity and mortality in children and adults living in countries of all income levels.1,2 Despite its importance, bronchiectasis has attracted little research. As a result, the management of bronchiectasis is often extrapolated from research on cystic fibrosis.1,2 However, this extrapolation might have unintended consequences. For example, recombinant human DNase, a mucolytic agent used successfully in cystic fibrosis, leads instead to increased exacerbations and hospital admissions, and accelerated pulmonary decline in adult patients with bronchiectasis.
The Lancet Respiratory Medicine
Medical and Health Sciences not elsewhere classified